... Health. Department of. Prenatal Drug Exposure and Neonatal Abstinence Syndrome in Northeast TN. Overview and Regional Snapshot

Similar documents
Neonatal Abstinence Syndrome Epidemiology, diagnosis, management and prevention

Substance-Exposed Newborn

Maternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015

Objectives. Care of the Neonate with Prenatal Opioid Exposure. What is Neonatal Abstinence Syndrome (NAS)? Increasing Incidence of NAS 8/27/2016

Care of the Neonate with Prenatal Opioid Exposure. Objectives. What is Neonatal Abstinence Syndrome (NAS)/ Neonatal Opiate Withdrawal Syndrome?

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

Product Labeling to Communicate Benefits and Risks of Treatment for Opioid Use Disorder in Pregnant Women. Hendrée E. Jones, PhD

Mental and Behavioral Health

Neonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)

Opioid use in pregnancy and Neonatal Abstinence Syndrome

4/19/2018. Opioid Use Disorder in Pregnancy OBJECTIVES ANTENATAL TESTING

Addressing the Opioid Epidemic in Tennessee

NOWS The Time Caring for the Infant with Neonatal Opiate Withdrawal Syndrome

Neonatal Abstinence: The epidemic Its Impact on All of Us

Opioid Use Disorder in Pregnancy. Neonatal Abstinence Syndrome

Opioid Abuse Treatment in Pregnancy

Opioid Use and Other Trends

SUBHEAD GOES HERE. Addressing Tennessee s Opioid Crisis. Natalie A. Tate, PharmD Vice President, Pharmacy

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids

Learning Objectives. Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons

MOMS Project Panel Overview

OPIOIDS IN JACKSON COUNTY A PUBLIC HEALTH PERSPECTIVE OPIOID AWARENESS COUNTY LEADERSHIP FORUM SHELLEY CARRAWAY, HEALTH DIRECTOR DATE

KRISANNA DEPPEN, MD FAMILY MEDICINE, ADDICTION MEDICINE GRANT MEDICAL CENTER-OHIOHEALTH COLUMBUS, OH

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond

The Impact of Neonatal Abstinence Syndrome: The View from a Rural Kentucky Hospital

Substance-Exposed Newborns

Neonatal Abstinence Syndrome:

What To Expect. Maternal Cannabis Use during Pregnancy and the Impacts on Offspring

2/24/2017. Pregnant Women Who Use Drugs: Stigma, Science and Society

Johann Hari. Truths 2/29/2016. From the street to the NICU. Treatment works

75,000 Too Many: How Can States, Providers & Advocates Address and Reverse the Trend of Babies Born with Dependence on Opioids?

Special SEOW Report: Behavioral Health Among Women in Maine

Supersedes Date None and Management Guidelines. Originating Dept. NICU Document Owner Dir., NICU Document applies to: NCH Required Not Required

Opiate Use in Reproductive Age Females

Pregnancy and Opioid Use

E. Omohundro, PhD, 3/15/2017 Office of Research 2

Barbour County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report Barbour County

Child Welfare and MOMS: Building Partnerships to Improve Care

Safe Babies Foster Parent Training Program

Mingo County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Opioids in Pregnancy. Beyond to Baby GENERAL INFO

Putnam County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

A System of Care Surrounding the Drug Exposed Neonate. Disclosures. Objectives 11/17/2015. I have no financial disclosures

Methadone and Pregnancy

Aligning Pain Management Community Public Health Presentation

Pocahontas County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Kanawha County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Summary of Recommendations...3. PEG: A Three-Item Scale Assessing Pain (Appendix A) Chronic Pain Flow Sheet Acute Pain Flow Sheet...

Effects of Prenatal Illicit Drug. Use on Infant and Child

Opioid Use Disorders and Pregnancy. Marcela Smid, MD Maternal-Fetal Medicine

Presented by DCF SunCoast Region: Kyle Teague, Melissa Worthen, Christina Cuoco, Nina Romeu, Dekesha Seay

Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC

Anesthetics, Local a / or Anesthesia, Epidural a / or Anesthesia, Obstetrical a / or Pain, Postoperative a / or Postpartum Period a

Clinical Management of Neonatal Abstinence Syndrome. Tricia L. Romesberg, DNP, MSN, ARNP, CNNP

The Opioid-Exposed Woman

Greenbrier County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Neonatal Abstinence Syndrome:

Effective Strategies for Addressing the Needs of Substance Exposed Newborns & their Families Dixie L. Morgese, BA, CAP, ICADC.

Neonatal Abstinence Syndrome (NAS)

Pregnancy, Opioid Addiction, and Care Issues in Virginia

Non-Pharmacologic Treatment for Infants with Neonatal Abstinence Syndrome (NAS)

Neonatal Abstinence Syndrome

INTRODUCTION. Baltimore, Maryland 6 School of Medicine West Virginia University, Morgantown, West Virginia

Neonatal Abstinence Syndrome In Kentucky. Annual Report. From the Public Health Neonatal Abstinence Syndrome Reporting Registry

Opiate Use Disorder and Opiate Overdose

Buprenorphine & Controlled Substance Treatment Agreement

Multidisciplinary Management of the Opioid Crisis To Optimize Perinatal Outcome in a Rural Women s Clinic Population

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program

The Impact of Addiction on Infant Mortality

HEALthy Brain and Child Development (HBCD) Study. Technical Assistance Webinar February 6, 2019

Addressing Substance Abuse To Improve Well-Being in Child Welfare Systems Current Trends, Continuing Challenges

An Adaptive Reinforcement-Based Treatment (RBT) Intervention for Pregnant Substance Dependent Women

Opioid Use in Pregnant Women and Prenatal Care. Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard

Talking with your doctor

Medication for the Treatment of Addiction (MAT)

Lori A. Shook, MD Division of Neonatology Kentucky Children s Hospital University of Kentucky Medical Center

Neonatal Drug Withdrawal

Neonatal Abstinence Syndrome and Maternal Substance Abuse in Tennessee

Understanding Prenatal Drug Exposure

What does it mean? What can we do?

Neonatal abstinence syndrome

Texas Strategies to Address the Opioid Crisis and Neonatal Abstinence Syndrome

THE OPIOID DEPENDENT MOTHER AND NEWBORN - AN UPDATE

Data-Driven Multidisciplinary Approaches to Reduce Prescription Drug Abuse in Kentucky Hal Rogers PDMP Grant. Action Team Meeting.

Public Policy Statement on Substance Use, Misuse, and Use Disorders During and Following Pregnancy, with an Emphasis on Opioids

Protecting Children s Safety: How Prescription Drug Monitoring Programs Can Assist An Update Presenter: John L. Eadie Moderator: Cindy Rodgers

HELPING OUR MOST VULNERABLE POPULATIONS IMPACTED BY THE OPIOID CRISIS: PREGNANT WOMEN, THEIR INFANTS, AND THOSE RECEIVING CHILD WELFARE SERVICES

PREGNANCY SMOKING AND CHILD OUTCOMES FROM BIRTH TO 15 MONTHS: FINDINGS FROM NORTHEAST TENNESSEE. Beth Bailey, PhD

Bench Guide for Opioid-Involved Dependency Cases *

Assessing Opioid Misuse and Overdose Using Prescription Drug Monitoring Programs (PDMP) and Other Data Sources

Perinatal Opioid Use: Understanding and Aligning Response between Systems

Brief History of Methadone Maintenance Treatment

National Strategies for Local Solutions

Oregon s Syndemic: Substance Use, Overdose, STIs, associated conditions and IDU-related infections. Framework and Response Models

4/12/2018. Opioid Addiction and Prescribing. Disclosure Statement of Financial Interest

Neonatal Abstinence Syndrome

Marijuana During Pregnancy: An Overview

Science = Solutions For Substance Use Disorders and Infant Outcomes. Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

Transcription:

Department of... Health Prenatal Drug Exposure and Neonatal Abstinence Syndrome in Northeast TN Overview and Regional Snapshot Cynthia C. Thomas, DO, MPH, Assistant Health Officer, Northeast Regional Health Office

What is Neonatal Abstinence Syndrome (NAS)? The term Neonatal Abstinence Syndrome (NAS) refers to a group of signs and symptoms that may occur in infants withdrawing from drug dependency following inutero drug exposure Abstinence syndromes may occur with repeated exposure to substances characterized by dependency Dependency occurs when receptors in the body are repeatedly exposed to a substance and, as a result, only function normally in the presence of that substance; absence of the substance results in physiologic signs and symptoms of withdrawal The most common class of substances associated with NAS are the opiates/opioids

NAS is a clinical diagnosis based on: History/evidence of exposure Clinical signs and symptoms of withdrawal Not all infants with in-utero drug exposure will show signs and symptoms of withdrawal However, all infants with in-utero drug exposure are at risk for adverse outcomes

Infants exposed in-utero to substances that may cause dependence are potentially at risk of withdrawal following birth NAS may be related to: Prescription drugs obtained with a prescription Prescription drugs obtained without a prescription Illicit drugs NAS may be related to use, misuse, abuse or addiction

Clinical diagnosis of NAS is based on: History/Evidence of exposure: Maternal report, maternal testing Infant urine, meconium, hair, or umbilical cord testing Clinical signs/symptoms of withdrawal Modified Finnegan Neonatal Scoring System Central Nervous System Metabolic/Vasomotor/Respiratory Gastrointestinal

Goal of treatment during neonatal withdrawal is to alleviate short-term symptomatology to allow healthy feeding, growth and maternal (caregiver) bonding First line CNS/GI/Respiratory/Vasomotor support measures Pharmacologic therapy with opioid replacement +/- adjunctive medications as needed Sutter MB et al. Neonatal Opioid Withdrawal Syndrome. Obstet Gynecol Clin N Am. 41 (2014) 317-334

Although NAS can be anticipated and managed at birth it is a preventable condition Prevent maternal exposure to substances that cause dependency Increase awareness of risks associated with opioid use Increase awareness of and adherence to guidelines for the outpatient management of non-malignant chronic pain Promote the responsible disposal of prescription drugs through take back events and drop off locations Prevent diversion and accidental ingestion through the use of lock boxes Increase awareness of the importance of taking prescription medications only as prescribed Increasing access to comprehensive treatment for alcohol and substance use Prevent unintended pregnancy in women of reproductive age who are not seeking pregnancy and are already exposed or at high risk of exposure Increasing awareness of the risks of opioid use during pregnancy Ensuring access to reproductive health education, family planning counseling and services

Between 2000 and 2012, the NAS hospitalization rate increased approximately fifteenfold Since NAS surveillance began in 2013, the total number of cases of NAS has continued to increase but the rate of NAS diagnoses (#NAS cases per 1,000 live births) has remained relatively stable with increases not reaching statistical significance Impacts of NAS extend beyond the diagnosis and management of the acute withdrawal syndrome Miller AM and Warren MD (2015). Neonatal Abstinence Syndrome Surveillance Annual Report 2015. Tennessee Department of Health, Nashville, TN.

NAS Surveillance Data 2013-2015 Geographic distribution: Rates of NAS are lowest in West Tennessee and increase in an easterly fashion Highest rates of NAS occurred in Northeast and East Regions and Sullivan County Sources of exposure: When categorized into mutually exclusive categories of exposure: 48.5% of cases were exposed to prescription drugs only 26.8% were exposed only to illicit or diverted drugs 23.2% were exposed to a mix of prescription and illicit or diverted drugs Since 2013, there has been a statistically significant increase in the percentage of NAS cases exposed only to prescription drugs Among cases exposed to only prescription drugs, 81.3% were exposed to medications used in medication assisted treatment Miller AM and Warren MD (2015). Neonatal Abstinence Syndrome Surveillance Annual Report 2015. Tennessee Department of Health, Nashville, TN.

Rates of NAS in the Northeast Region have consistently been among the highest rates in the state Five of seven counties in the Northeast Region showed a worsening of case rates between 2013 and 2015 68.3% of cases reported in the Northeast Region were exposed to prescription drugs only Miller AM and Warren MD (2015). Neonatal Abstinence Syndrome Surveillance Annual Report 2015. Tennessee Department of Health, Nashville, TN.

Opportunities to better understand, respond to, and prevent maternal substance use, prenatal substance exposure, and neonatal abstinence syndrome exist across the spectrum from pre-conception to long term follow up of affected infants --

Tennessee Department of Health Neonatal Abstinence Syndrome Health Topic Page https://www.tn.gov/health/topic/nas Background Information Reporting Resources Additional NAS Resources Reports and Publications NAS Surveillance Summary Archive NAS Update Archive NAS Research Projects